Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-Hu mice

Journal of Infectious Diseases

Volumn 181, Issue 3, 2000, Pages 921-926

  Goldstein, Harris ^a   Pettoello Mantovani, Massimo ^a   Bera, Tapan K ^b   Pastan, Ira H ^b   Berger, Edward A ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHIMERIC PROTEIN; LAMIVUDINE; RITONAVIR; TOXIN; ZIDOVUDINE;

ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; VIRUS LOAD;

ANIMALS; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HIV-1; HUMANS; LIVER; MICE; MICE, SCID; RECOMBINANT FUSION PROTEINS; THYMUS GLAND; VIRAL ENVELOPE PROTEINS;

EID: 0034081778     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315351     Document Type: Article

References (32)

1. 1. Saag MS, Schooley RT. Antiretroviral chemotherapy. Curr Clin Top Infect Dis 1998; 18:154-79.
2. 2. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291-5.
3. 3. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-300.
4. 4. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94:13193-7.
5. + T cells during primary HIV1 infection. Proc Natl Acad Sci USA 1998; 95:8869-73.
6. + T cells provides a mechanism for lifelong persistence of HIV1, even in patients on effective combination therapy. Nat Med 1999; 5:512-7.
7. 7. Zhang H, Dornadula G, Beumont M, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998; 339:1803-9.
8. 8. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV1 infection. Science 1997; 276: 960-4.
9. 9. Natarajan V, Bosche M, Metcalf JA, Ward DJ, Lane HC, Kovacs JA. HIV1 replication in patients with undetectable plasma virus receiving HAART. Lancet 1999; 353:119-20.
10. 10. Martinez MA, Cabana M, Ibanez A, Clotet B, Arno A, Ruiz L. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Virology 1999; 256:180-7.
11. 11. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340:1605-13.
12. 12. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999; 340:1614-22.
13. 13. Hockett RD, Kilby JM, Derdeyn CA, et al. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med 1999; 189:1545-54.
14. 14. Gunthard HF, Frost SDW, Leigh-Brown AJ, et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 1999; 73:9404-12.
15. 15. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999; 282:1627-32.
16. + T cells. Science 1999; 286:1353-7.
17. 17. Montaner JSG, Harris M, Mo T, Harrigan PR. Rebound of plasma HIV viral load following prolonged suppression with combination therapy. AIDS 1998; 12:1398-9.
18. 18. Jubault V, Burgard M, Le Corfec E, Costagliola D, Rouzioux C, Viard JP. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy. AIDS 1998; 12:2358-9.
19. 19. Chun TW, Davey RT, Engel D, Lane HC, Fauci AS. Reemergence of HIV after stopping therapy. Nature 1999; 401:874-5.
20. 20. Neumann AU, Tubiana R, Calvez V, et al. HIV1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. AIDS 1999; 13:677-83.
21. 21. Pincus SH. Therapeutic potential of antiHIV immunotoxins. Antiviral Res 1996; 33:1-9.
22. 22. Chaudhary VK, Mizukami T, Fuerst TR, et al. Selective killing of HIV infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature 1988; 335:369-72.
23. 23. Berger EA, Moss B, Pastan I. Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART. Proc Natl Acad Sci USA 1998; 95: 11511-3.
24. 24. Ramachandran RV, Katzenstein DA, Wood R, Batts DH, Merigan TC. Failure of short term CD4PE40 infusions to reduce virus load in human immunodeficiency virus infected persons. J Infect Dis 1994; 170:1009-13.
25. 25. Davey RT, Boenning CM, Herpin BR, et al. Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. J Infect Dis 1994; 170: 1180-8.
26. 26. Pettoello-Mantovani M, Kollmann TR, Katopodis NF, et al. Thy/livSCIDhu mice: a system for investigating the in vivo effects of multidrug therapy on plasma viremia and human immunodeficiency virus replication in lymphoid tissues. J Infect Dis 1998; 177:337-46.
27. 27. Bera TK, Kennedy PE, Berger EA, Barbas CF III, Pastan I. Specific killing of HIV infected lymphocytes by a recombinant immunotoxin directed against the HIV1 envelope glycoprotein. Mol Med 1998; 4:384-91.
28. 28. Kreitman RJ, Wang QQ, Fitzgerald DJP, Pastan I. Complete regression of human B cell lymphoma xenografts in mice treated with recombinant antiCD22 immunotoxin RFB4(dsFv)PE38 at doses tolerated by cynomolgus monkeys. Int J Cancer 1999; 81:148-55.
29. 29. Kollmann TR, Kim A, Pettoello-Mantovani M, et al. Divergent effects of chronic HIV1 infection on human thymocyte maturation in SCIDhu mice. J Immunol 1995; 154:907-921.
30. 30. Ashorn P, Moss B, Weinstein JN, et al. Elimination of infectious human immunodeficiency virus from human T cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. Proc Natl Acad Sci USA 1990; 87:8889-93.
31. + T cells in HIV1 infected patients receiving highly active antiretroviral therapy. Nat Med 1999; 5:651-5.
32. 32. Kreitman RJ, Wilson WH, Robbins D, et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 1999; 94:3340-8.